THE search for biological aberrations in affective disorders has been intensified within the last few years1. Special attention has been given to the changes in the metabolites of 5-hydroxytryptamine (5-HT) and of catecholamines in the cerebrospinal fluid2. In this laboratory3 as well as in several others4,5 the blood platelet has been used as an easily obtainable model of 5-HT neurones. Studies on the storage, metabolism and uptake of 5-HT in various neurological and mental illnesses have been largely negative1,6,7 except in Down's syndrome8–10. Neither in schizophrenia6 nor in affective illness7 have any changes been found. By using low substrate concentrations and measuring the initial uptake rate, both the uptake kinetics in platelets and the inhibitory potencies of antidepressant drugs were recently shown to correlate well with those found in synaptosomes11. It was therefore of considerable interest to examine the kinetics of 5-HT uptake anew, in the platelets of certain psychiatric patients, notably those with manic-depressive illness. This report indicates that in the platelets of depressed patients the uptake of 5-HT is clearly decreased.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schildkraut, J. J., A. Rev. Pharmac., 13, 427–454 (1973).
Symposium (several authors), in Proceedings of the Sixth International Congress of Pharmacology, 3, (edit. by Tuomisto, J., and Paasonen, M. K., volume editor Airaksinen, M.), 243–332 (Pergamon, Oxford 1976).
Paasonen, M. K., in Proceedings of the Fifth International Congress of Pharmacology, 4, (edit. by Acheson, G. H., volume eds. Bloom, F. E., and Acheson, G. H.), 327–342 (Karger, Basel, 1973).
Pletscher, A., Br. J. Pharmac., 32, 1–16 (1968).
Sneddon, J. M., Progress in Neurobiology, 1, part 2,1 51–158 (Pergamon Oxford, 1973).
Lucas, A. R., Warner, K., and Gottlieb, J. S., Biol. Psychiat., 3, 123–128 (1971).
Shaw, D. M., MacSweeney, D. A., Woolcock, N., and Bevan-Jones, A. B., J. Neurol. Neurosurg. Psychiat., 34, 224–225 (1971).
Boullin, D. J., and O'Brien, R. A., J. Physiol., Lond., 212, 287–297 (1971).
Airaksinen, E. M., J. ment. Defic. Res., 15, 244–256 (1971).
Lott, I. T., Chase, T. N., and Murphy, D. L., Pediat. Res., 6, 730–735 (1972).
Tuomisto, J., J. pharm. Pharmac., 26, 92–100 (1974).
Lineweaver, H., and Burk, H., J. Am. chem. Soc., 56, 658–666 (1934).
Lingjaerde, O. Jr, FEBS Lett., 3, 103–106 (1969).
Sneddon, J. M., Br. J. Pharmac., 37, 680–688 (1969).
About this article
Frontiers in Neuroscience (2019)
Partially Defective Store Operated Calcium Entry and Hem(ITAM) Signaling in Platelets of Serotonin Transporter Deficient Mice
PLOS ONE (2016)
Hemiplegic migraine, seizures, progressive spastic paraparesis, mood disorder, and coma in siblings with low systemic serotonin
The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity
Developmental Neurobiology (2010)
Acta Neurologica Scandinavica (2009)